TY - JOUR
T1 - Use of the high-flow helmet CPAP non-invasive ventilation device designed in Peru in patients with severe acute respiratory syndrome (COVID-19)
T2 - A prospective multicenter study
AU - Mantari, José Luis
AU - Bonifacio, Diego
AU - Hinostroza, Fany Ponce
AU - Panduro, Roy
AU - Oliden, José
AU - Cuba, Lizbeth Mónica
AU - Salazar, José Luis
AU - Tito, Jenny
AU - García, Jorge A.
AU - Bendezú, María R.
AU - Pariona-Llanos, Ricardo
AU - Aguilar-Ramirez, Priscilia
AU - Alvarado, Angel T.
N1 - Publisher Copyright:
Copyright Mantari JL et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2024
Y1 - 2024
N2 - High-flow non-invasive ventilation (NIV) devices reduce the morbidity and mortality of COVID-19. The objective was to evaluate the use of the non-invasive ventilation device with high-flow helmet CPAP designed in Peru in patients with severe acute respiratory syndrome (COVID-19) hospitalized in the emergency services of five hospitals. Prospective multicenter and cross-sectional observational study from five hospitals from July to August 2020. 19 patients were recruited and divided into two groups (G-1 n = 10; G-2 n = 9) applying clinical and gasometric parameters as indicators of disease evolution upon hospital admission and within 24 hours. A progressive increase in these parameters was observed in those patients who used the NIV CPAP helmet within the first 24 hours. In G-01, improvement was evident in 90% (n = 9/10): PaO2 (range 48–137; average: 82.49 ± 8.07; p-value = 0.008), CO2 (25.2–51.0; 36.62 ± 2.62; p-value p = 0.327), and the PaO2/FiO2 coefficient (87–318; 191.5 ± 18.68). 10% of patients did not progress optimally, being subjected to endotracheal intubation and invasive mechanical ventilation. In G-02 the values were %SatO2 (range 92–98; 96 ± 0.76) and the SaO2/FiO2 coefficient (214–228; 223.2 ± 1.80), indicating significant improvement within 24 hours (p < 0.001). It is concluded that the use of the CPAP helmet non-invasive ventilation (NIV) device contributes to improving gasometric values and clinical condition. Being an alternative to recover typical cases of COVID-19 in all hospitals in Peru.
AB - High-flow non-invasive ventilation (NIV) devices reduce the morbidity and mortality of COVID-19. The objective was to evaluate the use of the non-invasive ventilation device with high-flow helmet CPAP designed in Peru in patients with severe acute respiratory syndrome (COVID-19) hospitalized in the emergency services of five hospitals. Prospective multicenter and cross-sectional observational study from five hospitals from July to August 2020. 19 patients were recruited and divided into two groups (G-1 n = 10; G-2 n = 9) applying clinical and gasometric parameters as indicators of disease evolution upon hospital admission and within 24 hours. A progressive increase in these parameters was observed in those patients who used the NIV CPAP helmet within the first 24 hours. In G-01, improvement was evident in 90% (n = 9/10): PaO2 (range 48–137; average: 82.49 ± 8.07; p-value = 0.008), CO2 (25.2–51.0; 36.62 ± 2.62; p-value p = 0.327), and the PaO2/FiO2 coefficient (87–318; 191.5 ± 18.68). 10% of patients did not progress optimally, being subjected to endotracheal intubation and invasive mechanical ventilation. In G-02 the values were %SatO2 (range 92–98; 96 ± 0.76) and the SaO2/FiO2 coefficient (214–228; 223.2 ± 1.80), indicating significant improvement within 24 hours (p < 0.001). It is concluded that the use of the CPAP helmet non-invasive ventilation (NIV) device contributes to improving gasometric values and clinical condition. Being an alternative to recover typical cases of COVID-19 in all hospitals in Peru.
KW - COVID-19
KW - CPAP helmet
KW - high-flow ventilation
KW - respiratory failure
KW - ventilatory support
UR - http://www.scopus.com/inward/record.url?scp=85212763710&partnerID=8YFLogxK
U2 - 10.3897/PHARMACIA.71.E135653
DO - 10.3897/PHARMACIA.71.E135653
M3 - Artículo
AN - SCOPUS:85212763710
SN - 0428-0296
VL - 71
SP - 1
EP - 9
JO - Pharmacia
JF - Pharmacia
ER -